

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/198264 A1

(51) International Patent Classification:

C12N 9/48 (2006.01) C12N 9/64 (2006.01)

(21) International Application Number:

PCT/US2020/024521

(22) International Filing Date:

24 March 2020 (24.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/824,157	26 March 2019 (26.03.2019)	US
62/823,927	26 March 2019 (26.03.2019)	US
62/931,737	06 November 2019 (06.11.2019)	US

(71) Applicant: **ENCODIA, INC.** [US/US]; 11125 Flintkote Avenue, Suite B, San Diego, CA 92121 (US).

(72) Inventors: **DESAI, Kevin**; 11125 Flintkote Avenue, Suite B, San Diego, CA 92121 (US). **GUNDERSON, Kevin, L.**; 11125 Flintkote Avenue, Suite B, San Diego, CA 92121 (US). **JAMES, Robert, C.**; 11125 Flintkote Avenue, Suite B, San Diego, CA 92121 (US). **SHI, Lei**; 11125 Flintkote Avenue, Suite B, San Diego, CA 92121 (US). **VERESPY, Stephen, III**; 11125 Flintkote Avenue, Suite B, San Diego, CA 92121 (US).

(74) Agent: **CHEN, Peng** et al.; Rimon, P.C., One Embarcadero Center, Suite 400, San Francisco, CA 94111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS

FIG. 1A



(57) Abstract: Compositions and methods are provided for the inhibition, treatment and/or prevention of degenerative myelopathy (DM) or amyotrophic lateral sclerosis (ALS). In accordance with the instant invention, nucleic acid molecules for inhibiting the expression of the superoxide dismutase 1 gene (SOD) are provided. In a particular embodiment, the nucleic acid molecules comprise an annealing domain operably linked to at least one effector domain, wherein the annealing domain hybridizes to the pre-mRNA of SOD (e.g., canine or human) and wherein the effector domain hybridizes to the U1 snRNA of U1 snRNP.

WO 2020/198264 A1